[Nature Medicine] Researchers performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with large B cell lymphoma treated with CD19 CAR-T products.

[Experimental Hematology & Oncology] Scientists showed a relapsed and refractory thyroid cancer patient treated with thyroid-stimulating hormone receptor + (TSHR) CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19.

[Cell Research] Scientists developed healthy donor-derived, CD7-targeting CAR-T cells with genetic modifications to resist fratricide, graft-versus-host disease and allogeneic rejection, as well as to potentiate antitumor function.

[Stem Cell Reports] The authors developed a single-cell 3D spatial correlation (sc3DSC) method to track transplanted MSCs based on deep tissue microscopy of fluorescent nanoparticles (fNPs) and immunofluorescence of key proteins.

[Bone Marrow Transplantation] In 394 patients diagnosed with de novo acute myeloid leukemia who had a normal karyotype, the genetic profiling via targeted deep sequencing of 45 genes revealed 59 patients carrying secondary-type mutations.

[Journal of Clinical Investigation] Researchers developed CAR T cells directed against one of the targets, FOLR1, and demonstrated their pre-clinical efficacy against CBFA2T3-GLIS2 acute megakaryoblastic leukemia using in vitro and xenograft models.

[Stem Cells Translational Medicine] Researchers evaluated the potential of Tan IIA drug-loaded nanoparticles to improve iPSC-derived neural stem cells engraftment and efficacy, thus potentially leading to enhanced cellular, tissue, and functional recovery in a translational pig ischemic stroke model.

[Signal Transduction and Targeted Therapy] The authors describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.

[Nature Reviews Clinical Oncology] Investigators discuss examples from the past decade of the use of patient-derived xenograft models for precision oncology, from translational research to drug discovery.

[Neurona Therapeutics] Neurona Therapeutics announced the presentation of a clinical case study from the initial dose cohort of the Phase I/II first-in-human epilepsy clinical trial of its lead program, NRTX-1001.

[Artiva Biotherapeutics, Inc.] Artiva Biotherapeutics, Inc. announced that the US FDA has cleared the company’s investigational new drug (IND) application for AB-201. AB-201 is an allogeneic HER2-targeted CAR NK cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing.

[Cell Reports] In models of cutaneous squamous cell carcinoma, investigators discovered a non-epithelial-mesenchymal transition function for the transcription factor Snail in maintaining the stemness of epidermal keratinocytes.